12 Health Care Stocks Moving In Thursday's After-Market Session

Benzinga · 04/03 21:05
Gainers
- Impact BioMedical (AMEX:IBO) shares increased by 94.6% to $0.9 during Thursday's after-market session. The company's market cap stands at $10.3 million.
- Entero Therapeutics (NASDAQ:ENTO) shares moved upwards by 85.35% to $0.81. The market value of their outstanding shares is at $3.8 million.
- Sangamo Therapeutics (NASDAQ:SGMO) shares rose 29.54% to $0.81. The market value of their outstanding shares is at $180.9 million.
- Aldeyra Therapeutics (NASDAQ:ALDX) shares rose 15.19% to $1.63. The market value of their outstanding shares is at $97.0 million.
- Ernexa Therapeutics (NASDAQ:ERNA) shares moved upwards by 10.49% to $0.2. The company's market cap stands at $10.4 million.
- Coya Therapeutics (NASDAQ:COYA) shares increased by 8.19% to $6.6. The company's market cap stands at $110.3 million.
Losers
- NeuroOne Medical Tech (NASDAQ:NMTC) stock declined by 36.2% to $0.55 during Thursday's after-market session. The company's market cap stands at $16.9 million.
- Virpax Pharmaceuticals (NASDAQ:VRPX) stock fell 28.95% to $0.47.
- Genprex (NASDAQ:GNPX) shares declined by 15.16% to $0.37. The market value of their outstanding shares is at $3.1 million.
- Bone Biologics (NASDAQ:BBLG) stock fell 13.37% to $0.75. The market value of their outstanding shares is at $1.8 million.
- Portage Biotech (NASDAQ:PRTG) stock declined by 9.28% to $5.67. The company's market cap stands at $9.3 million.
- Aditxt (NASDAQ:ADTX) stock declined by 7.53% to $5.16. The company's market cap stands at $5.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.